Abstract
The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 179-181 |
| Number of pages | 3 |
| Journal | Investigative Urology |
| Volume | 19 |
| Issue number | 3 |
| State | Published - 1981 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Chemoimmunotherapy of murine bladder cancer. / Stogdill, B. J.; Lamm, D. L.; Livingston, Robert B.
In: Investigative Urology, Vol. 19, No. 3, 1981, p. 179-181.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chemoimmunotherapy of murine bladder cancer
AU - Stogdill, B. J.
AU - Lamm, D. L.
AU - Livingston, Robert B
PY - 1981
Y1 - 1981
N2 - The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.
AB - The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.
UR - http://www.scopus.com/inward/record.url?scp=0019789034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019789034&partnerID=8YFLogxK
M3 - Article
C2 - 7298287
AN - SCOPUS:0019789034
VL - 19
SP - 179
EP - 181
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 3
ER -